GET THE APP

Short Bowel Syndrome, Gut Failure and Nutrition
Journal of Clinical Trials

Journal of Clinical Trials
Open Access

ISSN: 2167-0870

+44 20 3868 9735

Editorial - (2011) Volume 1, Issue 1

Short Bowel Syndrome, Gut Failure and Nutrition

Trevor A Winter*
Stanford School of Medicine, Stanford, CA 94305, USA
*Corresponding Author: Trevor A Winter, MD, FACG, PhD, Associate Professor of Medicine, Stanford School of Medicine, Stanford, CA 94305, USA Email:

Definition of Short Bowel Syndrome

The normal small intestine length is 300 to 800 cm, dependent on the mode of measurement, either radiological, surgical or necropsy [1-3]. Short bowel syndrome is generally considered to occur when there is less than 200 cm remaining. Short bowel may be consequent to congenital abnormalities, necrotizing enterocolitis, extensive agangliosis, and volvulus in children, and following surgery for ischemia, Crohn’s disease, tumors and trauma in adults. A “functional short bowel” may result from refractory celiac sprue, chronic intestinal pseudo-obstruction, and radiation enteritis. Short bowel syndrome may be defined as “reduction of functioning gut mass below the minimum amount necessary for adequate water and electrolyte absorption and adequate digestion and absorption of nutrients” [4,5].

Absorption in the small bowel

Most digestion and absorption in the small bowel occurs in the first 150 cm. Vitamin B12 and bile salts are absorbed in the distal ileum. The distal ileum provides a brake, through the effects of peptide YY, GLP-I, neurotensin and the ileocecal valve [6-8]. PYY and GLP-1 are produced by the neuroendocrine (L) cells of the ileum and colon, as well as in nerves of the enteric nervous system and stimulated by incompletely digested fats. PYY and GLP-1 inhibits vagally stimulated gastric acid secretion, and gastric and intestinal motility [7-10]. The ileocecal valve also prevents contamination of the small bowel with colonic bacteria [11]. Removal of the ileocecal valve therefore increases the risk of bacterial overgrowth in the small bowel.

Following small bowel resection, possibly as a consequence of increased gastrin levels, and decreased PYY and GLP-1 in patients without a colon, gastric hypersecretion occurs in the first 6 months [12,13]. This may result in inactivation of pancreatic secretion, and irritation of the ileum resulting in more diarrheas. Proton pump inhibitor therapy is therefore required in the early management of short bowel patients.

The ileum, in particular, has the capability of adapting over a period of 1 to 2 years, with increase in height and diameter of the villi leading to a greater absorptive area. Glucagon-like peptide 2 (GLP-2), is secreted by endocrine cells in the ileum and colon, and stimulates hyperplasia, and increases the absorptive capacity of the residual small bowel [14,15]. Intestinal adaption is also thought to be enhanced by enteroglucagon, growth hormone, epidermal growth factor, cholecystokinin, gastrin, insulin, neurotensine as well as the amino acid glutamine [16,17].

Because of reduced surface area for absorption, as well as reduced bile salts, patients with short gut syndrome will have significant fat malabsorption. Hydroxylation of the fats by colic bacteria, if the colon is intact, will result in the production of hydoxy-fatty acids, which have cathartic activities, and may aggravate the diarrhea [18-20]. Fats also compete with oxalate for absorption to calcium. Increased fats will therefore increase the availability of oxalate for absorption in the colon, and increases the risk of oxalate renal stones. A low fat, high calcium diet may therefore be indicated in patients with short gut with intact colons.

Non-absorbed carbohydrates (monosaccharides and oligosaccharides) may be fermented by lactobacilli, and other bacteria in the colon to produce D-lactate [21,22]. D-lactate cannot be metabolized by L-lactate dehydrogenase, possibly resulting in a severe metabolic acidosis and encephalopathy.

Importance of the colon

The presence of the colon is important in short bowel syndrome. The presence of the colon is associated with increased PYY levels, providing a “colonic brake” [8,23,24]. With increased delivery on nonabsorbed carbohydrates, particularly fiber, colonic bacteria produce short chain fatty acids which are absorbed, together with water and electrolytes and contribute significantly to nutrient and fluid balances. The presence of at least 50% of the colon is equivalent to an additional 50 cm of small bowel [25]. Up to 1000 kcal/day may be salvaged by the colon [26].

Problems of fluid and electrolyte balance generally occur when there is less than 120 cm small bowel remaining. Less than 60cm of small bowel (with an intact colon), and less than 100 cm without a colon invariably necessitates long-term parenteral nutrition [27].

Therapeutic interventions

A variety of therapeutic interventions have been tried in patients with short bowel syndrome to reduce the dependence on TPN.

Szkudlarek et al. [28] randomized 8 patients with short bowel syndrome, who had been dependent on parenteral nutrition for an average of 7 years, to a double blind crossover study of placebo and growth hormone (mean 0.12 mg/kg/day) with oral glutamine (mean 28 g/day) and parenteral glutamine (mean 5.2 g/day) for 28 days. Results showed that growth hormone with glutamine did not improve intestinal absorption of energy, (baseline, placebo, treatment, mean 46%, 48%.46% of oral intake, respectively), carbohydrate (71%, 70%, 71%), fat (20%, 15%, 18%), nitrogen (27%, 18%, 19%) compared to placebo or baseline [28]. The authors concluded that high dose growth hormone and glutamine with a normal diet administered for 4 weeks did not improve intestinal absorption.

Seguy et al. [29] investigated the role of low dose growth hormone in patients with short bowel syndrome who were parenteral nutrition dependent [29]. Twelve adult patients with short bowel syndrome who had received home parenteral nutrition for a mean of 7 ± 1 years were randomized in a double-blind, placebo-controlled, crossover study to receive growth hormone 0.05 mk/kg/day and placebo for two 3-week periods separated by a 1-week washout period. Patients were all on an unrestricted hyperphagic diet providing 2.1 ± 0.2 times the basal metabolic rate (53 ± 6 kcal/kg/day) with 0.34 ± 0.05 g nitrogen /kg/ day. Results revealed that treatment with growth hormone increased intestinal absorption of energy (15% ± 5%, P < 0.002), nitrogen (14%6%, P<0.04), and carbohydrates (10% ± 4%, P<0.04). The effects on fat absorption were not significantly different (12% ± 8%, NS). This represented 37% ± 16% of total parenteral energy delivery. D-xylose absorption also increased with growth hormone treatment (1.2 ± 0.2 vs 0.8 ± 0.2 mmol/l). Body mass increased significantly (57.2 ± 2.4 kg vs. 55.2 ± 2.2 kg, P<0.003), as did lean body mass (46.9 ± 2.7 kg vs 45.2 ± 2.5 kg, P<0.002). Citrulline levels were not significantly different (20 μmol/l vs. 17 ± 2 μmol/l)

Byrne et al investigated the role of a concomitant high carbohydrate diet with growth hormone and glutamine [30]. The investigators randomized 41 adults with short bowel syndrome (36 with colons) dependent on parenteral nutrition, to oral glutamine (30 g/day) plus growth hormone (0.1 mg/kg), oral glutamine (30 g/day) plus growth hormone placebo, and glutamine placebo plus growth hormone (0.1 mg/kg/day) for a period of 4 weeks. The patients were also commenced on an optimal diet, rich in protein (≈20%), low to moderate in fat (≈30%), and high in complex carbohydrates (≈50%). Results revealed the group receiving growth hormone, glutamine, and diet had the greatest reduction of parenteral nutrition volume (7.7 ± 3.2 L/week), parenteral nutrition calories (5751 ± 2082 kcal/week), and parenteral nutrition infusions (4 ± 1 infusions/week). The group receiving growth hormone, glutamine placebo, and diet showed greater reductions in parenteral nutrition volume (5.9 ± 3.8 L/week), parenteral nutrition calories (4338 ± 1858 kcal/week), and parenteral nutrition infusions (3 ± 2 infusions/week), than corresponding reductions in the glutamine and diet group (3.8 ± 2.4 L/week, 2633 ± 1341 kcal/week, and 2 ± 1 infusions/week). The effect was maintained for 3 months in the growth hormone, glutamine and diet group.

In a review of five studies [28-33], including the three outlined above, of human growth hormone and glutamine for patients with short bowel syndrome, Wales PW et al concluded that human growth hormone with or without glutamine appeared to provide benefit in terms of increased weight, lean body mass, energy absorption, and nitrogen absorption [34]. However, the effects were generally short-lived after cessation of therapy, raising the question of the clinical utility of the treatment. The evidence, to date, is inconclusive to recommend this therapy.

The role of teduglutide, a GLP-2 analog, was investigated in 83 patients with short bowel syndrome dependent on parenteral support (fluids, electrolytes or nutrients) at least three times a week for a period of at least 12 months prior to the study [35]. Patients were randomized to receive subcutaneous teduglutide 0.10 mg/kg/day (n=32), 0.05 mg/kg/day (n=35), or placebo (n=16) for 24 weeks. Parenteral fluids were decreased at 4 weekly intervals if intestinal fluid absorption (48 hr urine volumes) increased ≥ 10%. Responders were subjects who demonstrated reductions of ≥ 20% in parenteral volumes from baseline at weeks 20 and 24. A graded response score (GRS), which accounted for both intensity and duration of a response at 24 weeks, was introduced as the primary endpoint. Results revealed that using the GRS criteria, teduglutide at a dose of 0.05 mg/kg had a significant effect compared to placebo (16/35 vs. 1/16; P<0.07), whereas at a dose of 1.0 mg/kg it did not (8/32 vs 1/16; P=0.16). Plasma citrulline levels were significantly increased in both the teduglutide 0.1 mg/kg/ day group (16.6 ± 8.3 μmol/l to 32.2 ± 15.4 mol/l; P<0.0001), and the teduglutide 0.5 mg/kg/day group (18.0 ± 10.3 μmol/l to 29.5 ± 16.2 μmol/l; P<0.0001), but not in the placebo group (22.2 ± 10.6 μmol/l to 24.2 ± 13.6 μmol/l). The authors conclude that teduglutide was safe, well tolerated, intestinotropic with suggested pro-absorptive effects facilitating reduction in parenteral support in patients with short bowel syndrome.

Management of short bowel syndrome

1. Use of proton pump inhibitors to inhibit the excessive gastric secretion

2. Use of antimotilty agents (loperamide, immodium, tinc of opium and codeine) to slow gut transit and increase dwell-time

3. Complex carbohydrates should comprise 50-60% total calories in patients with intact colons

4. Fats should be restricted in patients with intact colons.

5. Vitamin B12 supplementation in patients who have had ileal resection

6. Cholestyramine should be tried in patients with ileal resection <100 cm and intact colons.

7. Oral rehydration solutions containing at least 90 mEq/l of sodium, and the avoidance of dilute (tap) water

8. Supplementation of fat soluble vitamins (A,D,E, and K if colon absent), as well as zinc, selenium, magnesium and calcium

9. Avoidance of simple sugars (monosaccharides and oligosaccharides) due to risk of D-lactic acidosis

10. Parenteral nutrition in those patients in whom fluid and electrolyte balance, and caloric intake cannot be maintained.

Surgical Options

Surgical options include segmental reversal of the small bowel (Biachi procedure), and serial transverse enteroplasty (STEP procedure). Small bowel transplant is considered in patients who have developed life-threatening complications of short bowel syndrome and TPN therapy.

References

  1. Bryant J (1924) Observations upon the growth and length of the human intestine. Am J Med Sci 167: 499-520.
  2. Crenn P, Haniche M, Valleur P, Hautefeuille P, Rambaud J, et al. (1996) Surgical versus radiological evaluation of remaining small bowel length (RSBL) in short bowel syndrome (SBS) (abstr). Gastroenterology 110: A321.
  3. Fanucci A, Cerro P, Fraracci L, Ietto F (1984) Small bowel length measured by radiography. Gastrointest Radiol 9: 349-351.
  4. Fleming CR, Remington M (1981) eds. Intestinal failure. London: Churchill Livingstone
  5. O'Keefe SJ, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, et al. (2006) Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol 4: 6-10.
  6. Dumoulin V, Moro F, Barcelo A, Dakka T, Cuber JC (1998) Peptide YY Glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum. Endocrinology 139: 3780-3786.
  7. Maljaars J, Peters HP, Masclee AM (2007) Review article: The gastrointestinal tract: neuroendocrine regulation of satiety and food intake. Aliment Pharmacol Ther 2: 241-250.
  8. Wen J, Phillips SF, Sarr MG, Kost LJ, Holst JJ (1995) PYY and GLP-1 contribute to feedback inhibition from the canine ileum and colon. Am J Physiol 269: G945-952.
  9. Schirra J, Goke B (2005) The physiological role of GLP-1 in human: incretin, ileal brake or more? Regul Pept 128: 109-115.
  10. Van Citters GW, Lin HC (2006) Ileal brake: neuropeptidergic control of intestinal transit. Curr Gastroenterol Rep 8: 367-373.
  11. Gracey M (1979) The contaminated small bowel syndrome: pathogenesis, diagnosis, and treatment. Am J Clin Nutr 32: 234-243.
  12. Adrian TE, Savage AP, Fuessl HS, Wolfe K, Besterman HS, et al. (1987) Release of peptide YY (PYY) after resection of small bowel, colon, or pancreas in man. Surgery 101:715-719.
  13. D'Sa AA, Buchanan KD (1977) Role of gastrointestinal hormones in the response to massive resection of the small bowel. Gut 18: 877-881.
  14. Martin GR, Beck PL, Sigalet DL (2006) Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. World J Gastroenterol 12: 4117-4129.
  15. Martin GR, Wallace LE, Sigalet DL (2004) Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 286: G964-972.
  16. Sham J, Martin G, Meddings JB, Sigalet DL (2002) Epidermal growth factor improves nutritional outcome in a rat model of short bowel syndrome. J Pediatr Surg 37: 765-769.
  17. Cisler JJ, Buchman AL (2005) Intestinal adaptation in short bowel syndrome. J Investig Med 53: 402-413.
  18. Ammon HV, Phillips SF (1974) Inhibition of ileal water absorption by intraluminal fatty acids. Influence of chain length, hydroxylation, and conjugation of fatty acids. J Clin Invest 53: 205-210.
  19. Ammon HV, Thomas PJ, Phillips SF (1974) Effects of oleic and ricinoleic acids on net jejunal water and electrolyte movement. Perfusion studies in man. J Clin Invest 53: 374-379.
  20. Wanitschke R, Ammon HV (1978) Effects of dihydroxy bile acids and hydroxy fatty acids on the absorption of oleic acid in the human jejunum. J Clin Invest 61:178-186.
  21. Hove H, Mortensen PB (1995) Colonic lactate metabolism and D-lactic acidosis. Dig Dis Sci 40: 320-330.
  22. Mayne AJ, Handy DJ, Preece MA, George RH, Booth IW (1990) Dietary management of D-lactic acidosis in short bowel syndrome. Arch Dis Child 65: 229-231.
  23. Andrews NJ, Irving MH (1992) Human gut hormone profiles in patients with short bowel syndrome. Dig Dis Sci 37: 729-732.
  24. Nightingale JM, Kamm MA, van der Sijp JR, Ghatei MA, Bloom SR, Lennard- Jones JE (1996) Gastrointestinal hormones in short bowel syndrome. Peptide YY may be the 'colonic brake' to gastric emptying. Gut 39: 267-272.
  25. Nightingale JM, Lennard-Jones JE, Gertner DJ, Wood SR, Bartram CI (1992) Colonic preservation reduces need for parenteral therapy, increases incidence of renal stones, but does not change high prevalence of gall stones in patients with a short bowel. Gut 33:1493-1497.
  26. Nordgaard I, Hansen BS, Mortensen PB (1996) Importance of colonic support for energy absorption as small-bowel failure proceeds. Am J Clin Nutr 64: 222-2231.
  27. Szkudlarek J, Jeppesen PB, Mortensen PB. (2000) Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study. Gut 47: 199-205.
  28. Seguy D, Vahedi K, Kapel N, Souberbielle JC, Messing B (2003) Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients: a positive study. Gastroenterology 124: 293-302.
  29. Byrne TA, Wilmore DW, Iyer K, Dibaise J, Clancy K, et al. (2005) Growth hormone, glutamine, and an optimal diet reduces parenteral nutrition in patients with short bowel syndrome: a prospective, randomized, placebo-controlled, double-blind clinical trial. Ann Surg 242: 655-661.
  30. Ellegard L, Bosaeus I, Nordgren S, Bengtsson BA (1997) Low-dose recombinant human growth hormone increases body weight and lean body mass in patients with short bowel syndrome. Ann Surg 225: 88-96.
  31. Scolapio JS (1999) Effect of growth hormone, glutamine, and diet on body composition in short bowel syndrome: a randomized, controlled study. JPEN J Parenter Enteral Nutr 23: 309-312.
  32. Scolapio JS, Camilleri M, Fleming CR, Oenning LV, Burton DD, et al. (1997) Effect of growth hormone, glutamine, and diet on adaptation in short-bowel syndrome: a randomized, controlled study. Gastroenterology 113:1074-1081.
  33. Wales PW, Nasr A, de Silva N, Yamada J (2010) Human growth hormone and glutamine for patients with short bowel syndrome. Cochrane Database.
  34. Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, et al. (2011) Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 60: 902-914.
Citation: Winter TA (2011) Short Bowel Syndrome, Gut Failure and Nutrition. J Clinic Trials 1:e101.

Copyright: © 2011 Winter TA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.